期刊
CANCER IMMUNOLOGY RESEARCH
卷 8, 期 7, 页码 856-868出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/2326-6066.CIR-20-0020
关键词
-
资金
- Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine
- Center for AIDS Research (CFAR) at the University of Miami Miller School of Medicine
- Dodson Interdisciplinary Immunotherapy Institute
- Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami
Vaccination of patients against neoantigens expressed in concurrent tumors, recurrent tumors, or tumors developing in individuals at risk of cancer is posing major challenges in terms of which antigens to target and is limited to patients expressing neoantigens in their tumors. Here, we describe a vaccination strategy against antigens that were induced in tumor cells by downregulation of the peptide transporter associated with antigen processing (TAP). Vaccination against TAP downregulation-induced antigens was more effective than vaccination against mutation-derived neoantigens, was devoid of measurable toxicity, and inhibited the growth of concurrent and future tumors in models of recurrence and premalignant disease. Human CD8(+) T cells stimulated with TAP(low) dendritic cells elicited a polyclonal T-cell response that recognized tumor cells with experimentally reduced TAP expression. Vaccination against TAP downregulation-induced antigens overcomes the main limitations of vaccinating against mostly unique tumor-resident neoantigens and could represent a simpler vaccination strategy that will be applicable to most patients with cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据